Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation

Nature Cell Biology

Volumn 13, Issue 3, 2011, Pages 282-291

  Kubota, Yuji ^a,b   O'Grady, Pauline ^a   Saito, Haruo ^a   Takekawa, Mutsuhiro ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; RAF PROTEIN; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SUMOYLATION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE KINASES; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; NIH 3T3 CELLS; RAS PROTEINS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 79952280325     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb2169     Document Type: Article

References (65)

1. Calvo, F., Agudo-Ibanez, L. & Crespo, P. The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. Bioessays 32, 412-421 (2010).
2. Yao, Z. & Seger, R. The ERK signaling cascade-views from different subcellular compartments. Biofactors 35, 407-416 (2009).
3. Avruch, J. MAP kinase pathways: Therst twenty years. Biochim. Biophys. Acta 1773, 1150-1160 (2007). (Pubitemid 47125973)
4. Raman, M., Chen, W. & Cobb, M. H. Differential regulation and properties of MAPKs. Oncogene 26, 3100-3112 (2007). (Pubitemid 46763006)
5. Dhanasekaran, D. N. & Johnson, G. L. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene 26, 3097-3099 (2007). (Pubitemid 46763009)
6. Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
7. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
8. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
9. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
10. Meloche, S. & Pouyssegur, J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26, 3227-3239 (2007). (Pubitemid 46763017)
11. Malumbres, M. & Barbacid, M. RAS oncogenes: Therst 30 years. Nat. Rev. Cancer 3, 459-465 (2003).
12. Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7, 295-308 (2007). (Pubitemid 46480970)
13. Young, A. et al. Ras signaling and therapies. Adv. Cancer Res. 102, 1-17 (2009).
14. Mody, A., Weiner, J. & Ramanathan, S. Modularity of MAP kinases allows deformation of their signalling pathways. Nat. Cell Biol. 11, 484-491 (2009).
15. Johnson, G. L. & Gomez, S. M. Sequence patches on MAPK surfaces dene proteinprotein interactions. Genome Biol. 10, 222 (2009).
16. Tanoue, T., Adachi, M., Moriguchi, T. & Nishida, E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2, 110-116 (2000).
17. Enslen, H. & Davis, R. J. Regulation of MAP kinases by docking domains. Biol. Cell 93, 5-14 (2001). (Pubitemid 33040855)
18. Bardwell, A. J., Frankson, E. & Bardwell, L. Selectivity of docking sites in MAPK kinases. J. Biol. Chem. 284, 13165-13173 (2009).
19. Takekawa, M., Tatebayashi, K. & Saito, H. Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol. Cell 18, 295-306 (2005). (Pubitemid 41350535)
20. Geiss-Friedlander, R. & Melchior, F. Concepts in SUMOylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947-956 (2007). (Pubitemid 350176509)
21. Melchior, F., Schergaut, M. & Pichler, A. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28, 612-618 (2003). (Pubitemid 38352808)
22. Johnson, E. S. Protein modification by SUMO. Annu Rev. Biochem. 73, 355-382 (2004). (Pubitemid 39050373)
23. Seeler, J. S. & Dejean, A. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4, 690-699 (2003).
24. Hay, R. T. SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 17, 370-376 (2007). (Pubitemid 47375105)
25. Muller, S., Hoege, C., Pyrowolakis, G. & Jentsch, S. SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2, 202-210 (2001).
26. Kim, J. H. et al. Roles of SUMOylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat. Cell Biol. 8, 631-639 (2006). (Pubitemid 43827357)
27. Steffan, J. S. et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 304, 100-104 (2004). (Pubitemid 38451465)
28. Cheng, J., Kang, X., Zhang, S. & Yeh, E. T. SUMO-specific protease 1 is essential for stabilization of HIF1- during hypoxia. Cell 131, 584-595 (2007). (Pubitemid 350007694)
29. Kamitani, T., Nguyen, H. P. & Yeh, E. T. Preferential modification of nuclear proteins by a novel ubiquitin-like molecule. J. Biol. Chem. 272, 14001-14004 (1997). (Pubitemid 27232794)
30. Uchimura, Y., Nakamura, M., Sugasawa, K., Nakao, M. & Saitoh, H. Overproduction of eukaryotic SUMO-1- and SUMO-2-conjugated proteins in Escherichia coli. Anal Biochem. 331, 204-206 (2004). (Pubitemid 38881579)
31. Ohren, J. F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197 (2004).
32. Kranenburg, O., Verlaan, I. & Moolenaar, W. H. Dynamin is required for the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase. J. Biol. Chem. 274, 35301-35304 (1999). (Pubitemid 129512814)
33. Ory, S., Zhou, M., Conrads, T. P., Veenstra, T. D. & Morrison, D. K. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr. Biol. 13, 1356-1364 (2003). (Pubitemid 37029425)
34. Terai, K. & Matsuda, M. Ras binding opens c-Raf to expose the docking site for mitogen-activated protein kinase kinase. EMBO Rep. 6, 251-255 (2005). (Pubitemid 40485621)
35. Xu, J. et al. Insulin enhances growth hormone induction of the MEK/ERK signaling pathway. J. Biol. Chem. 281, 982-992 (2006).
36. Galperin, E. & Sorkin, A. Endosomal targeting of MEK2 requires RAF, MEK kinase activity and clathrin-dependent endocytosis. Traffic 9, 1776-1790 (2008).
37. Liu, Y., Fisher, D. A. & Storm, D. R. Intracellular sorting of neuromodulin (GAP-43) mutants modified in the membrane targeting domain. J. Neurosci. 14, 5807-5817 (1994). (Pubitemid 24307778)
38. Liang, X., Lu, Y., Neubert, T. A. & Resh, M. D. Mass spectrometric analysis of GAP-43/neuromodulin reveals the presence of a variety of fatty acylated species. J. Biol. Chem. 277, 33032-33040 (2002). (Pubitemid 34984818)
39. Jakobs, A. et al. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyse function of protein SUMOylation. Nat. Methods 4, 245-250 (2007). (Pubitemid 46358875)
40. Bardwell, A. J., Flatauer, L. J., Matsukuma, K., Thorner, J. & Bardwell, L. A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission. J. Biol. Chem. 276, 10374-10386 (2001).
41. Xu, B., Stippec, S., Robinson, F. L. & Cobb, M. H. Hydrophobic as well as charged residues in both MEK1 and ERK2 are important for their proper docking. J. Biol. Chem. 276, 26509-26515 (2001).
42. Chiu, V. K. et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 4, 343-350 (2002). (Pubitemid 34521029)
43. Lerner, E. C. et al. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15, 1283-1288 (1997). (Pubitemid 27429743)
44. Karandikar, M., Xu, S. & Cobb, M. H. MEKK1 binds raf-1 and the ERK2 cascade components. J. Biol. Chem. 275, 40120-40127 (2000). (Pubitemid 32064638)
45. Saltzman, A. et al. hUBC9 associates with MEKK1 and type I TNF-receptor and stimulates NffiB activity. FEBS Lett. 425, 431-435 (1998). (Pubitemid 28178846)
46. Li T., et al., SUMOylation of heterogeneous nuclear ribonucleoproteins zincnger proteins, and nuclear pore complex proteins: a proteomic analysis. Proc. Natl Acad. Sci. USA 101, 8551-8556 (2004). (Pubitemid 38745808)
47. Russell, M., Lange-Carter, C. A. & Johnson, G. L. Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1). J. Biol. Chem. 270, 11757-11760 (1995).
48. Eletr, Z. M., Huang, D. T., Duda, D. M., Schulman, B. A. & Kuhlman, B. E2 conjugating enzymes must disengage from their E1 enzymes before E3- dependent ubiquitin and ubiquitin-like transfer. Nat. Struct. Mol. Biol. 12, 933-934 (2005). (Pubitemid 41486719)
49. Dadke, S. et al. Regulation of protein tyrosine phosphatase 1B by SUMOylation. Nat. Cell Biol. 9, 80-85 (2007). (Pubitemid 46024200)
50. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185 (1995).
51. Murphy, L. O. & Blenis, J. MAPK signal specificity: the right place at the right time. Trends Biochem. Sci. 31, 268-275 (2006). (Pubitemid 43674354)
52. Yamamoto, T. et al. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr. Biol. 16, 1171-1182 (2006). (Pubitemid 43867293)
53. Lu, Z., Xu, S., Joazeiro, C., Cobb, M. H. & Hunter, T. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol. Cell 9, 945-956 (2002). (Pubitemid 34626666)
54. Witowsky, J. A. & Johnson, G. L. Ubiquitylation of MEKK1 inhibits its phospho- rylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. J. Biol. Chem. 278, 1403-1406 (2003). (Pubitemid 36801363)
55. Sobko, A., Ma, H. & Firtel, R. A. Regulated SUMOylation and ubiquitination of DdMEK1 is required for proper chemotaxis. Dev. Cell 2, 745-756 (2002). (Pubitemid 34650071)
56. Kang, J. S., Saunier, E. F., Akhurst, R. J. & Derynck, R. The type I TGF- receptor is covalently modified and regulated by SUMOylation. Nat. Cell Biol. 10, 654-664 (2008). (Pubitemid 351772931)
57. Desterro, J. M., Rodriguez, M. S. & Hay, R. T. SUMO-1 modification of ifiB- inhibits NF-B activation. Mol. Cell 2, 233-239 (1998). (Pubitemid 128373648)
58. Sebolt-Leopold, J. S. & Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947 (2004). (Pubitemid 39626217)
59. Arimoto, K., Fukuda, H., Imajoh-Ohmi, S., Saito, H. & Takekawa, M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat. Cell Biol. 10, 1324-1332 (2008).
60. Akiyama, T. et al. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol. Cell Biol. 11, 833-842 (1991). (Pubitemid 21895432)
61. Giroux, S. et al. Embryonic death of Mek1-decient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 9, 369-372 (1999). (Pubitemid 29194878)
62. Wohlschlegel, J. A., Johnson, E. S., Reed, S. I. & Yates, J. R. 3rd Improved identification of SUMO attachment sites using C-terminal SUMO mutants and tailored protease digestion strategies. J. Proteome Res. 5, 761-770 (2006).
63. Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063-1066 (2000). (Pubitemid 30398356)
64. Cowley, S., Paterson, H., Kemp, P. & Marshall, C. J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841-852 (1994). (Pubitemid 24187682)
65. Cuevas, B. D., Winter-Vann, A. M., Johnson, N. L. & Johnson, G. L. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene 25, 4998-5010 (2006).